Related Experiment Video

Updated: Jul 7, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

[Methodological approaches of clinical studies with targeted therapies]

Nicolas Penel1, Julia Saleron, Amélie Lansiaux

  • 1Département de cancérologie générale, Centre Oscar-Lambret, 3, rue F.-Combemale, 59020 Lille, France.

Bulletin Du Cancer
|February 29, 2008
PubMed

Insights

Designing molecular targeted therapies requires unique methods. Phase I trials focus on biological effect dose, not maximal tolerated dose, while Phase III studies validate biomarkers and use discontinuation designs.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trial Design

Context:

  • Molecular targeted therapies represent a paradigm shift in cancer treatment, necessitating specialized clinical trial methodologies.
  • Traditional dose-finding methods, like establishing the maximal tolerated dose (MTD) in Phase I studies, are often insufficient for these agents due to rare dose-limiting toxicities.

Purpose:

  • To outline the specific methodological approaches required for the development of molecular targeted therapies.
  • To describe the distinct designs and objectives of Phase II and Phase III clinical trials for molecular targeted therapies.

Summary:

  • Phase I trials for molecular targeted therapies often identify the biologically active dose (BAD) rather than the MTD, focusing on target engagement and biological effect.
  • Phase II trials employ various designs (selection, randomized, stratified) tailored to specific clinical situations and therapeutic hypotheses.
  • Phase III trials are characterized by discontinuation designs and the crucial validation of biomarkers, serving as surrogate endpoints or predictive classifiers.

Impact:

  • This methodological framework is essential for efficiently and effectively evaluating novel molecular targeted therapies.
  • Optimized trial designs ensure the accurate assessment of efficacy and safety, facilitating the translation of these agents to clinical practice.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...